Clinical Trial Update: Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating gemcitabine hydrochloride and docetaxel with or without bevacizumab in advanced or recurrent uterine leiomyosarcoma; study terminated w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stage Iiia Uterine Sarcoma
• Stage Iiib Uterine Sarcoma
• Stage Iiic Uterine Sarcoma
• Uterine Corpus Leiomyosarcoma
• Uterine Corpus Sarcoma
• Uterine Sarcoma Stages Iiic
• Uterine Sarcoma Stages Iva
• Uterine Sarcoma Stages Ivb

Drugs mentioned

• Bevacizumab (bevacizumab)
• DOCETAXEL (DOCETAXEL)
• Gemcitabine hydrochloride (Gemcitabine hydrochloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma | Phase 3 | Status: TERMINATED | Results posted: 2017-07-14